Do not inj intravascularly. Adequate treatment provisions including epinephrine inj should be available for immediate use if anaphylactic/anaphylactoid reaction occur. History of anaphylactic, anaphylactoid or other immediate reactions (eg, hives, swelling of mouth & throat, difficulty breathing, hypotension, shock) subsequent to egg ingestion. Individual or family history of convulsions, cerebral injury or other condition in which stress due to fever should be avoided. Temp elevation. Individuals w/ current thrombocytopenia may develop more severe thrombocytopenia following vaccination. Individuals who experienced thrombocytopenia w/ 1st dose of M-M-R II (or its component vaccines) may develop thrombocytopenia w/ repeat doses. Closely monitor HIV-infected vaccinees for vaccine-preventable diseases. May result in temporary tuberculin skin sensitivity depression. Administer tuberculin test either before, simultaneously w/, or at least 4-6 wk after M-M-R II. May not protect 100% of vaccinees. Do not give Ig concurrently. Individuals planning to travel abroad (if not immune) can acquire MMR. Vaccination has been recommended for susceptible individuals in high-risk groups (eg, college students, healthcare workers & military personnel). Vaccination of individuals exposed to wild-type measles may provide some protection if vaccinated w/in 72 hr of exposure. Immunization of susceptible non-pregnant adolescent & adult females of childbearing age. Advise women of childbearing age not to become pregnant for 1 mth after vaccination. Inform postpubertal females of frequent occurrence of generally self-limited arthralgia &/or arthritis beginning 2-4 wk after vaccination. Previously unvaccinated childn >12 mth who are in contact w/ susceptible pregnant woman should receive live attenuated rubella vaccine to reduce risk of exposure of the pregnant woman. Not to be administered during pregnancy. Lactation. Childn under treatment for TB who have not experienced disease exacerbation when immunized w/ live measles virus vaccine; untreated tuberculous childn. Infant <6 mth (measles) & <12 mth (mumps & rubella).